Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1164

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 4
Chunk 1164
---
 Company. The transfer agent’s address is 1110 Centre Pointe Curve, Suite 101,
Mendota Heights, Minnesota 55120, and its telephone number is (800) 401-1957.

ITEM
6. [RESERVED]

ITEM
7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Special
Note Regarding Forward-Looking Statements

All
statements other than statements of historical fact included in this Annual Report on Form 10-K, including, without limitation, statements
under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s
financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements.
When used in this Annual Report on Form 10-K, words such as “anticipate,” “believe,” “estimate,”
“expect,” “intend” and similar expressions, as they relate to us or the Company’s management, identify
forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and
information currently available to, the Company’s management. Actual results could differ materially from those contemplated by
the forward-looking statements as a result of certain factors detailed in our filings with the SEC.

The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial
statements and the notes thereto contained elsewhere in this Annual Report on Form 10-K. Certain information contained in the discussion
and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Unless the context otherwise requires,
“JNS,” “we,” “us,” “our,” or the “Company” refers to Jupiter Neurosciences,
Inc.

Business
Overview

We are a clinical stage research and development company.
We have developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Our platform product, JOTROL,
an enhanced oral formulation of resveratrol, has many potential indications of use for rare diseases. In the larger disease areas, we
are primarily targeting Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease.

In December 2024, we received gross proceeds of $11
million in a registered public offering (“Public Offering”) of 2,750,000 shares of our common stock, par value $0.0001 per
share (“common stock”) at a price of $4.00 per